A strategic adjuvant therapy of osteosarcoma.
Twenty-one patients with osteogenic sarcoma of the limbs were treated with an early combination of 1,750 rad whole lung irradiation, alternate cyclic chemotherapy with high-dose methotrexate, vincristine, mitomycin C, adriamycin, immidazol carboxamide (DTIC), cyclophosphamide, and intercalated immuno-BCG. The primary lesion was treated either by amputation or an 8,000 rad irradiation. Patients have been followed up for 6-29 months. Three patients relapsed, respectively, after 8, 11, and 22 months. All three patients had a long delay in completing the first part of treatment (first cycles A and B and lung irradiation). The 18 other patients are disease-free. Local relapses have not been observed. The toxicity of this protocol appears to be acceptable, but a longer follow-up is necessary to more precisely discern the efficacy and tolerance of the lung to this combined treatment.
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology; D012516:Osteosarcoma / Q000188:drug therapy / Q000628:therapy*; D011879:Radiotherapy Dosage